Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: A multicentric cooperative study

Anti-Cancer Drugs

Volumn 8, Issue 5, 1997, Pages 459-465

  Neri, B ^a   Garosi, V L ^a,b   Intini, C ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b PFIZER INC   (United States)

Author keywords

Medroxyprogesterone acetate; Quality of life; Randomized study; Solid tumor

Indexed keywords

ANABOLIC AGENT; ANTINEOPLASTIC AGENT; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; CACHEXIA; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPERVOLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREMOR;

EID: 0030872974     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199706000-00007     Document Type: Article

References (21)

1. Donovan K, Samson-Fisher RW, Redman S. Measuring quality of life in cancer patients. J Clin Oncol 1989; 7: 959-68.
2. De Haes JCM, Van Knip-Penger FCE. The quality of lie of cancer patients: a review of the literature. Soc Sci Med 1985; 20: 809-17.
3. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. Can Med Ass J 1986; 134: 889-95.
4. Bardelli D, Saracci R. Measuring the quality of life in cancer clinical trials: a sample survey of published trials. NICC Tech Rep 1978; 36: 75-94.
5. Fayers PM, Jones DR. Measuring and analyzing quality of life in cancer clinical trials: a review. Stat Med 1983; 2: 429-46.
6. Haks GW, Truemant V, Twycross RG. Corticosteroids in terminal cancer patients. A prospective analysis of current practice. Postgrad Med J 1983; 59: 702-6.
7. Twycross RG, Guppy D. Prednisolone in terminal breast and bronchogenic cancer. Practitionner 1985; 225: 57-9.
8. Moertel C, Schutt AJ, Reitemeier RJ, Hahan RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33: 1607-9.
9. Bruera E, Roca E, Cedaro L, Carraro S, Chacon NR. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69: 751-4.
10. Robustelli della Cuna G, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in pre-terminal patients: a placebo controlled, multicenter study. Eur J Cancer Clin Oncol 1989; 25: 1817-21.
11. Cruz JM, Muss HB, Brockschmidt JK, Evans GW. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high dose therapy. Semin Oncol 1990; 17 (suppl 9): 63-7.
12. Loprinzi CL. A controlled trial of megestrol acetate treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990; 82: 1127-32.
13. Tchekmedyan NS. Megestrolacetate in cancer anorexia and weight loss. Proc Am Soc Clin Oncol 1990; 9: 336.
14. Bruera E, McMillan K, Hanson J, Kuhen N, McDonald RN. A controlled trial of megestrolacetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990; 66: 1279-82.
15. Lelli G, Angelelli B, Giambiasi ME. The anabolic effect of high dose medroxyprogesterone acetate in oncology. Pharmacol Res Commun 1983; 15: 561-8.
16. Talbot DC, Slevin ML, Joel SP. A randomized double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 1988; 58: 267-9.
17. Gruppo Cooperativo Italiano per lo studio del medrossiprogesterone acetato in oncolgia. Medrossiprogesterone acetato per via orale: maneggevolezza, accettabilità ed impatto sulla qualità della vita di una nuova formulazione granulare in pazienti con neoplasie in fast avanzata. Farm Ter 1990; 7: 157-62.
18. Scevola D, Zambelli A, Bottari G. Appetite stimulation and body weight gain with medroxyprogesterone acetate in AIDS anorexia and cachexia. Farm Ter 1991; 8: 77-83.
19. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1976; 34: 585-612.
20. Tamburini M, Rosso S, Gamba A, Mencaglia E, De Conno F, Ventafridda V. A therapy impact questionnaire for quality-of-life assessment in advanced cancer research. Ann Oncol 1992; 3: 565-70.
21. Lelli G, Angelelli B, Zanichelli L. The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patients. Chemioterapia 1984; 5: 327-9.